Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
- 30 June 1993
- journal article
- clinical trial
- Published by Elsevier in Psychiatry Research
- Vol. 47 (3) , 267-280
- https://doi.org/10.1016/0165-1781(93)90084-t
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- A controlled trial of propoxyphene and naltrexone in patients with tourette's syndromeAnnals of Neurology, 1991
- Opiate therapy and self‐harming behavior in tourette's syndromeMovement Disorders, 1991
- Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patientsLife Sciences, 1991
- MU receptor-serotonin link in opioid induced hyperactivity in miceLife Sciences, 1990
- ?2-Adrenergic, k-Opiaie, and PrPurinergic Autoreceptors Have Mutually Antagonistic Effects: A New Regulatory Mechanism?Journal of Neurochemistry, 1989
- Opiate Withdrawal Unmasks Touretteʼs SyndromeClinical Neuropharmacology, 1988
- Anatomy of CNS opioid receptorsTrends in Neurosciences, 1988
- Elevated CSF dynorphin A [1–8] in Tourette's syndromeLife Sciences, 1988
- Nonopiate Effects of Dynorphin and Des-Tyr-DynorphinScience, 1982
- Behavioral effects of dynorphin — a novel opioid neuropeptideNeuropharmacology, 1980